178 related articles for article (PubMed ID: 2508092)
1. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
Fitzgerald DJ; Fitzgerald GA
Proc Natl Acad Sci U S A; 1989 Oct; 86(19):7585-9. PubMed ID: 2508092
[TBL] [Abstract][Full Text] [Related]
2. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
Fitzgerald DJ; Wright F; FitzGerald GA
Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
[TBL] [Abstract][Full Text] [Related]
3. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
Yasuda T; Gold HK; Yaoita H; Leinbach RC; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
J Am Coll Cardiol; 1990 Sep; 16(3):714-22. PubMed ID: 2117620
[TBL] [Abstract][Full Text] [Related]
5. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
6. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis.
Pratico D; Murphy NP; Fitzgerald DJ
J Pharmacol Exp Ther; 1997 Jun; 281(3):1178-85. PubMed ID: 9190851
[TBL] [Abstract][Full Text] [Related]
7. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
[TBL] [Abstract][Full Text] [Related]
8. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
[TBL] [Abstract][Full Text] [Related]
10. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Haskel EJ; Prager NA; Sobel BE; Abendschein DR
Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
[TBL] [Abstract][Full Text] [Related]
11. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
[TBL] [Abstract][Full Text] [Related]
13. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
Mellott MJ; Connolly TM; York SJ; Bush LR
Thromb Haemost; 1990 Dec; 64(4):526-34. PubMed ID: 2128137
[TBL] [Abstract][Full Text] [Related]
14. A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction.
Kerins DM; Shuh M; Kunitada S; Fitzgerald GA; Fitzgerald DJ
J Pharmacol Exp Ther; 1991 Apr; 257(1):487-92. PubMed ID: 1708425
[TBL] [Abstract][Full Text] [Related]
15. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Martin U; Dörge L; Fischer S
Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
[TBL] [Abstract][Full Text] [Related]
16. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
Fitzgerald DJ; Hanson M; FitzGerald GA
J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
[TBL] [Abstract][Full Text] [Related]
17. Reperfusion, specific thrombin inhibition and reocclusion after thrombolysis.
Chesebro JH; Fuster V
J Am Coll Cardiol; 1990 Sep; 16(3):723-5. PubMed ID: 2117621
[No Abstract] [Full Text] [Related]
18. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
Uriuda Y; Wang QD; Hatori N; Nordlander R; Sjöquist PO; Mattsson C; Rydén L
J Pharmacol Toxicol Methods; 1998 Mar; 39(2):81-9. PubMed ID: 9694166
[TBL] [Abstract][Full Text] [Related]
19. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
20. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
